The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 dotatate (Lutathera) for...
The FDA has approved nogapendekin alfa inbakicept-pmln, which stimulates immune cells to fight bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG),...
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for adult patients...
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory...
Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who...
A new treatment regimen that includes a Bruton’s tyrosine kinase inhibitor was approved for follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanubrutinib (Brukinsa) in combination with obinutuzumab...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of patients with unresectable...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More